Study of Maintenance of the Efficiency and Adverse Effects of Pharmacological Treatments in Sex Offenders With Paraphilia
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 18, 2020
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well certain medications work for men with paraphilia, a condition that can lead to sexual offenses. The researchers want to find out which treatments, like anti-androgens (medications that lower testosterone) or SSRIs (a type of antidepressant), are effective and what side effects might occur over time. They aim to gather information that could help improve treatment options for this group, as current studies are limited and have not thoroughly explored the long-term effects of these medications.
To be eligible for this study, participants must be men aged 18 to 65 who have committed at least one sexual offense and have been diagnosed with paraphilia. They should also be receiving medication for their condition, either SSRIs or anti-androgens. Participants will be monitored over three years to see how well the treatments work and if they experience any side effects. This trial is important because it could provide valuable insights into the best approaches for treating paraphilia in a larger group of individuals than has been studied before.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Man
- • At least one sex offence
- • Paraphilia (DSM-5 criteria )
- • Receiving pharmacological treatment ( ISRS or anti-androgen or none of them)
- • Age between 18 and 65 years
- • Patient 100% covered by social security
- Exclusion Criteria:
- • no consent
- • female
- • aged under 18 or over 65 years
- • subject receiving simultaneous ISRS and anti-androgen treatment before enrolment
- • incarcerated
- • Subject under guardianship (patients under curatorship may however be included),
- • no social security registration
- • contraindications or allergies to treatments
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Florence THIBAUT, MD, PhD
Study Chair
CHU Cochin, Groupe Hospitalier Paris Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials